share_log

Private Companies Account for 57% of China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Ownership, While Individual Investors Account for 28%

Private Companies Account for 57% of China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Ownership, While Individual Investors Account for 28%

私營企業佔中國一致醫藥集團股份有限公司(SZSE:000028)57%的所有權,而個人投資者佔 28%
Simply Wall St ·  07/06 20:58

Key Insights

主要見解

  • The considerable ownership by private companies in China National Accord Medicines indicates that they collectively have a greater say in management and business strategy
  • The largest shareholder of the company is China National Pharmaceutical Group Corporation with a 57% stake
  • Institutional ownership in China National Accord Medicines is 15%
  • 中國一致藥業的私營企業大量持股表明它們在管理和業務策略方面擁有更大的權利。
  • 該公司最大的股東是中國醫藥集團有限公司,持有57%的股份。
  • 中國一致藥業的機構持股比例爲15%。

Every investor in China National Accord Medicines Corporation Ltd. (SZSE:000028) should be aware of the most powerful shareholder groups. We can see that private companies own the lion's share in the company with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

每個中國一致藥業股份有限公司(SZSE:000028)的投資者都應該了解最強大的股東群體。我們可以看到,私營企業佔有57%的股份。也就是說,如果股票上漲,該集團將獲益最多(或者如果出現衰退則會失去最多的利益)。

Meanwhile, individual investors make up 28% of the company's shareholders.

與此同時,個人投資者佔公司股東的28%。

Let's take a closer look to see what the different types of shareholders can tell us about China National Accord Medicines.

讓我們更近距離地觀察不同類型的股東如何爲我們提供中國一致藥業的信息。

ownership-breakdown
SZSE:000028 Ownership Breakdown July 7th 2024
SZSE:000028所有權結構分析 2024年7月7日

What Does The Institutional Ownership Tell Us About China National Accord Medicines?

機構持股結構分析

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

As you can see, institutional investors have a fair amount of stake in China National Accord Medicines. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at China National Accord Medicines' earnings history below. Of course, the future is what really matters.

如您所見,機構投資者在中國一致藥業擁有相當大的股份。這可能表明公司在投資界擁有一定的信譽度。然而,最好不要依賴所謂的機構投資者的認可。他們有時也會犯錯。如果多個機構同時改變對一隻股票的看法,股價可能會快速下跌。因此,值得看一下以下是中國一致藥業的收入歷史。當然,未來才是真正重要的。

earnings-and-revenue-growth
SZSE:000028 Earnings and Revenue Growth July 7th 2024
SZSE:000028業績和收入增長分析 2024年7月7日

We note that hedge funds don't have a meaningful investment in China National Accord Medicines. Our data shows that China National Pharmaceutical Group Corporation is the largest shareholder with 57% of shares outstanding. This essentially means that they have extensive influence, if not outright control, over the future of the corporation. Meanwhile, the second and third largest shareholders, hold 2.2% and 1.9%, of the shares outstanding, respectively.

我們注意到,對於中國一致藥業,對沖基金並沒有實質性的投資。我們的數據顯示,中國醫藥集團有限公司是最大的股東,持有57%的流通股。這基本上意味着,如果他們的股票上漲,他們將對公司的未來產生廣泛的影響,如果出現下降,則會失去大部分利益。同時,第二大和第三大股東,分別持有流通股的2.2%和1.9%。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

研究機構所有權是衡量和過濾股票預期表現的好方法。通過研究分析師的情緒也可以實現同樣的目的。由於有相當數量的分析師涵蓋這支股票,因此了解他們對未來的整體看法可能會有所幫助。

Insider Ownership Of China National Accord Medicines

中國一致藥業的內部持股分析

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

內部人員的定義在不同國家之間可能略有不同,但董事會成員始終計數。公司管理層回答董事會,在此應代表股東利益。值得注意的是,有時高級管理人員也在董事會上。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。

Our data suggests that insiders own under 1% of China National Accord Medicines Corporation Ltd. in their own names. But they may have an indirect interest through a corporate structure that we haven't picked up on. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own CN¥165k worth of shares. It is good to see board members owning shares, but it might be worth checking if those insiders have been buying.

我們的數據表明,公司管理層本人僅持有中國一致藥業股份有限公司的不到1%的股份。但是,他們可能通過一個我們尚未發現的公司結構獲得間接利益。它是一個大公司,因此即使擁有較小的相對利益,也可以在董事會和股東之間建立利益共同體。在這種情況下,管理層本人擁有165,000 人民幣的股份。看到董事會成員持有股份是好事,但最好還是查看這些管理層是否一直在進行購買。

General Public Ownership

一般大衆所有權

With a 28% ownership, the general public, mostly comprising of individual investors, have some degree of sway over China National Accord Medicines. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

有28%的股份屬於普通公衆,主要由個人投資者組成。因此,這種所有權雖然可能沒有足夠的影響力來爲他們謀取政策決策方面的優勢,但他們仍然可以對公司政策產生集體影響。

Private Company Ownership

私有公司的所有權

Our data indicates that Private Companies hold 57%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們的數據表明,私營公司持有該公司57%的股份。這些私營企業可能是關聯方。有時,內部人員通過持有私營公司的股權而不是以個人的身份利益參與公共公司。雖然很難得出任何全面的結論,但值得注意的是這可能是一個進一步研究的領域。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that China National Accord Medicines is showing 1 warning sign in our investment analysis , you should know about...

儘管考慮擁有公司所有權的不同群體非常重要,但更重要的是還有其他因素。請注意,我們的投資分析顯示,中國一致藥業存在一個警示信號,您應該了解這一點......

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論